Sam Brusco, Associate Editor02.20.24
Cagent Vascular has closed Series C financing in excess of $30 million. The round was led by U.S. Venture Partners (USVP) with participation from new investor Blue Ridge Medical and existing investors, including Sectoral Asset Management.
The company’s Serranator PTA serration balloon catheter has three embedded, serrated elements to modify plaque by creating linear, interrupted scoring along the endoluminal surface to help with arterial expansion. The Serranator’s mechanism of action, according to the company, has shown greater lumen gain than plain angioplasty balloons.
A recent Journal of Endovascular Therapy study compared the degree of elastic recoil—a dramatic loss of lumen gain that happens within 15 minutes of treatment—in Serranator-treated vs. plain balloon in below-the-knee lesions. The results showed 55% elastic recoil in the plain balloon group, compared to 6% in the Serranator group.
The company said the data points to potential improvement in people with chronic limb threatening ischemia, where arteries are prone to elastic recoil post-treatment, which reduces blood flow.
Serranator has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance and is meant for dilatation of lesions in the iliac, femoral, iliofemoral, popliteal and infrapopliteal arteries for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. It’s currently sold in the U.S. and holds a CE mark with limited distribution in Europe.
“We are pleased with the significant investment from U.S. Venture Partners and other new and existing investors. To date, we estimate that over 10,000 Serranator PTA Serration Balloon Catheters (Serranator) have been used to treat those suffering from Peripheral Artery Disease (PAD). This infusion of capital will increase our commercial reach, helping to provide greater access for healthcare providers and their patients,” said Carol A. Burns, Cagent’s CEO.
The company’s Serranator PTA serration balloon catheter has three embedded, serrated elements to modify plaque by creating linear, interrupted scoring along the endoluminal surface to help with arterial expansion. The Serranator’s mechanism of action, according to the company, has shown greater lumen gain than plain angioplasty balloons.
A recent Journal of Endovascular Therapy study compared the degree of elastic recoil—a dramatic loss of lumen gain that happens within 15 minutes of treatment—in Serranator-treated vs. plain balloon in below-the-knee lesions. The results showed 55% elastic recoil in the plain balloon group, compared to 6% in the Serranator group.
The company said the data points to potential improvement in people with chronic limb threatening ischemia, where arteries are prone to elastic recoil post-treatment, which reduces blood flow.
Serranator has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance and is meant for dilatation of lesions in the iliac, femoral, iliofemoral, popliteal and infrapopliteal arteries for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. It’s currently sold in the U.S. and holds a CE mark with limited distribution in Europe.
“We are pleased with the significant investment from U.S. Venture Partners and other new and existing investors. To date, we estimate that over 10,000 Serranator PTA Serration Balloon Catheters (Serranator) have been used to treat those suffering from Peripheral Artery Disease (PAD). This infusion of capital will increase our commercial reach, helping to provide greater access for healthcare providers and their patients,” said Carol A. Burns, Cagent’s CEO.